Form 4: Arcutis CEO Sells Shares for Tax Obligations

Arcutis Biotherapeutics CEO Todd Watanabe sold 19,833 shares of common stock on February 2, 2026, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported a sale of common stock.
• On February 2, 2026, 19,833 shares of common stock were sold at a weighted average price of $25.4984 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• These RSUs were granted on January 12, 2024, with 25% vesting annually on February 1st of each year, commencing February 1, 2025.
• Following this transaction, Todd Watanabe directly beneficially owns 721,306 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• The reported direct beneficial ownership also includes 602 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2025.
• Indirect beneficial ownership is reported through various trusts and an LLC, totaling 233,134 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine, pre-planned transaction by an executive to cover tax obligations associated with RSU vesting, which is a common practice and does not indicate a change in company fundamentals or executive sentiment.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued compensation and retention of a key executive.
• The transaction was conducted under a Rule 10b5-1(c) plan, demonstrating pre-planned and compliant insider trading.
• The executive also purchased 602 shares through the Employee Stock Purchase Plan on November 30, 2025, indicating ongoing investment in the company.

Negatives

• The sale of shares, even for tax purposes, reduces the executive's direct equity stake in the company.

Future Outlook

NA

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units.
• The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that routine insider sales, particularly those related to tax obligations from RSU vesting, are common across the biopharmaceutical industry. These transactions typically do not reflect a change in management's outlook on the company's prospects but are a standard part of executive compensation and tax planning.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership is held through The John Franklin Watanabe Trust, The Anderson Prest Watanabe Irrevocable Trust, Watanabe Ventures, LLC, and The Watanabe 2016 Irrevocable Trust. The Reporting Person disclaims beneficial ownership except to the extent of pecuniary interest.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, tax-related sale by an insider, not indicative of a change in company fundamentals.
• Management: The executive's direct equity stake is slightly reduced, but the overall compensation structure (RSUs) remains in place.

Next Steps

• Future annual vesting of the remaining Restricted Stock Units on February 1st of subsequent years, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned sale of shares by Arcutis Biotherapeutics' CEO to cover tax obligations arising from RSU vesting. Such transactions are common and typically do not signal a change in the company's fundamental outlook or the executive's confidence. The presence of a Rule 10b5-1 plan further reinforces the non-discretionary nature of the sale. Therefore, the filing itself does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate as the core investment thesis remains unaffected.

Keywords

Arcutis Biotherapeutics, ARQT, Todd Watanabe, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Rule 10b5-1, Employee Stock Purchase Plan, Biotherapeutics, Pharmaceutical